Medigen Vaccine Biologics Corporation (TPEX:6547)
Taiwan · Delayed Price · Currency is TWD 65.00
+1.90 (3.01%)
Aug 28, 2026, 1:30 PM CST
Medigen Vaccine Biologics Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 573.85 | 613.17 | 605.64 | 389.62 | 365.04 | 3,281 | |
Revenue Growth | -9.22% | 1.24% | 55.44% | 6.73% | -88.87% | 28413.03% |
Cost of Revenue | 212.3 | 248.5 | 209.22 | 159.4 | 577.64 | 975.96 |
Gross Profit | 361.55 | 364.67 | 396.42 | 230.22 | -212.6 | 2,305 |
Selling, General & Admin | 291.5 | 291.79 | 320.58 | 243.44 | 183.67 | 148.21 |
Research & Development | 251.17 | 338.57 | 221.51 | 1,201 | 1,140 | 1,193 |
Operating Expenses | 542.67 | 630.37 | 542.09 | 1,444 | 1,324 | 1,341 |
Operating Income | -181.12 | -265.69 | -145.67 | -1,214 | -1,536 | 963.73 |
Interest Expense | -13.58 | -8.8 | -18.89 | -37.57 | -26.89 | -6.02 |
Interest & Investment Income | 29.3 | 29.3 | 46.25 | 83.28 | 7.61 | 2.74 |
Currency Exchange Gain (Loss) | 10.63 | -29.33 | 38.35 | -0.33 | 28.86 | 7.52 |
Other Non Operating Income (Expenses) | - | 1.51 | -1.62 | 8.61 | 32.25 | -0.07 |
EBT Excluding Unusual Items | -154.77 | -273.02 | -81.57 | -1,160 | -1,494 | 967.9 |
Gain (Loss) on Sale of Investments | -0.08 | - | - | - | - | - |
Gain (Loss) on Sale of Assets | -12.99 | -9.2 | 0.41 | - | - | - |
Other Unusual Items | 1.07 | 0.5 | 0.7 | - | 19.86 | 442.36 |
Pretax Income | -166.77 | -281.71 | -80.47 | -1,160 | -1,475 | 1,410 |
Net Income | -166.77 | -281.71 | -80.47 | -1,160 | -1,475 | 1,410 |
Net Income to Common | -166.77 | -281.71 | -80.47 | -1,160 | -1,475 | 1,410 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 329 | 329 | 329 | 328 | 323 | 319 |
Shares Outstanding (Diluted) | 329 | 329 | 329 | 328 | 323 | 321 |
Shares Change | 0.01% | 0.03% | 0.10% | 1.50% | 0.73% | 15.82% |
EPS (Basic) | -0.51 | -0.86 | -0.24 | -3.53 | -4.56 | 4.42 |
EPS (Diluted) | -0.51 | -0.86 | -0.24 | -3.53 | -4.56 | 4.39 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -217.55 | -99.72 | 6.46 | -521.25 | -1,353 | 446.26 |
Free Cash Flow Per Share | -0.66 | -0.30 | 0.02 | -1.59 | -4.18 | 1.39 |
Gross Margin | 63.00% | 59.47% | 65.45% | 59.09% | -58.24% | 70.25% |
Operating Margin | -31.56% | -43.33% | -24.05% | -311.54% | -420.85% | 29.37% |
Profit Margin | -29.06% | -45.94% | -13.29% | -297.68% | -403.95% | 42.98% |
Free Cash Flow Margin | -37.91% | -16.26% | 1.07% | -133.78% | -370.64% | 13.60% |
EBITDA | -57.85 | -144.21 | -26.16 | -1,098 | -1,423 | 1,072 |
EBITDA Margin | -10.08% | -23.52% | -4.32% | -281.86% | - | 32.67% |
D&A For EBITDA | 123.28 | 121.49 | 119.5 | 115.64 | 112.91 | 108.34 |
EBIT | -181.12 | -265.69 | -145.67 | -1,214 | -1,536 | 963.73 |
EBIT Margin | -31.56% | -43.33% | -24.05% | - | - | 29.37% |